Legal Cannabis Market Size, Share, Growth and Forecast, 2025-2035

Licensed cannabis retail more than doubles by 2035

The legal cannabis market was valued at USD 39.84 billion in 2025 and is projected to increase from USD 43.19 billion in 2026 to USD 89.25 billion by 2035, registering a CAGR of 8.40% during 2025–2035. Demand comes from new U.S. adult-use states such as Ohio and Delaware, steady legal-channel gains in Canada, where sales rose 6.1% in the 2024/2025 fiscal year, and the opening of medical markets in Europe after Germany's 2024 Cannabis Act. Consumers are also shifting from flower to edibles, beverages, vapes and pre-rolls in U.S. and Canadian stores. North America held the largest regional share, 89.2% in 2025, led by state-licensed U.S. programs, while Europe is the fastest-growing region at 16.67% a year. The main regulatory change is the April 2026 federal rule that moved state-licensed medical marijuana to Schedule III, easing the federal tax burden on medical operators.

What counts as a legal cannabis sale?

Legal cannabis sales are retail purchases of THC cannabis through licensed stores, government retailers, pharmacies and authorized medical producers. Adult-use buyers shop in licensed dispensaries in U.S. states, Canadian provinces and a few other markets, while medical patients buy through dispensaries or, in Germany, Australia and the United Kingdom, mostly through pharmacies on prescription. Products include flower, pre-rolls, vapes and cartridges, concentrates, edibles and beverages.

The market excludes hemp-derived CBD and intoxicating hemp products sold outside cannabis licenses, illicit and grey-market sales, and equipment, testing and ancillary services. That boundary matters because hemp THC drinks and unlicensed sellers compete for the same consumers outside regulated sales data.

Adult-use and flower lead while edibles grow fastest

Adult-use leads by market type and grows faster

Based on market type, the market is categorized into adult-use and medical cannabis. Adult-use led with 73.0% of 2025 value and is also the faster-growing type at 8.88% a year, because most legal sales in the U.S. and Canada now go to recreational buyers and many patients switch to adult-use stores once they open. Medical sales remain large in Florida, Pennsylvania, Germany, Israel and Australia, and Schedule III treatment supports state medical licensees from 2026.

Flower leads the product mix while edibles and beverages grow fastest

Based on product, the market is categorized into flower, vapes and cartridges, edibles and beverages, pre-rolls and concentrates. Flower led with 41.5% of 2025 value, as it remains the cheapest and most familiar format in every legal market. Edibles and beverages grow fastest at 11.77% a year because low-dose gummies and cannabis drinks bring in consumers who do not smoke. Infused pre-rolls and live-resin vapes also gain share from flower.

Schedule III, new states and German prescriptions lift sales

Schedule III status frees cash for U.S. medical operators

U.S. federal policy is the largest swing factor, and in December 2025, Executive Order 14370 directed the attorney general to complete rescheduling quickly. A final rule in the Federal Register then placed FDA-approved marijuana products and state-licensed medical marijuana in Schedule III from April 28, 2026, with an expedited registration route. For those medical operators, Schedule III lifts the federal tax rule that blocks normal business deductions, freeing cash that operators can spend on stores, products and prices. A hearing on adult-use rescheduling ran from June 29 to July 15, 2026.

New adult-use states pull sales into the legal channel

New adult-use states still add demand, though more slowly than in the last decade. Ohio started adult-use sales in August 2024 and Delaware on Aug. 1, 2025, and Minnesota is building out its licensed store network. Each new state launch shifts purchases from the illicit market and from neighboring states into licensed adult-use stores, which keeps adult-use the larger and faster-growing market type.

Download Free Sample

Canada keeps taking share from illicit sellers

Canada shows how a mature legal market grows, as Statistics Canada reports that cannabis sales rose 6.1% to CAD 5.5 billion in the 2024/2025 fiscal year and 37.1% over three years, while governments collected CAD 2.5 billion in cannabis revenue. The country had 3,295 cannabis retail businesses with employees at the end of 2025, and 51.4% of retailers were small shops with 1 to four employees. However, falling prices and a crowded store network now hold Canadian sales growth to single digits.

Germany opens Europe's largest medical cannabis market

Germany's Cannabis Act took cannabis off the narcotics list in April 2024, making medical prescriptions easier to obtain and allowing home growing and non-profit clubs. Medical imports and telemedicine prescriptions rose sharply after the change, and other EU states are watching the German results. As a result, Europe is the fastest-growing region, building from a 4.1% share of 2025 value. Producers in Canada, Portugal and Germany that meet EU good manufacturing practice standards supply most of that demand.

Easy-dose formats and falling prices reshape store sales

Consumers shift from flower toward convenient formats

Flower still leads, but consumers are moving to pre-rolls, vapes, gummies and drinks that are easier to dose and use discreetly. Infused pre-rolls lead growth within pre-rolls, while live-resin and all-in-one vapes lift the vape category. Edibles and beverages grow fastest at 11.77% a year, so brands offering consistent low doses gain shelf space, while flower growers face pressure to add premium lines.

Price compression caps revenue in mature markets

In Canada and many older U.S. markets, prices per gram have fallen for several years as cultivation capacity outran demand. Lower prices win customers from illicit sellers but cap revenue growth, which is why North America grows at 7.57% a year, below the global rate. Producers respond with both premium craft lines and value brands, while weaker operators sell licenses or close, adding to multi-state operator consolidation.

Download Free Sample

Pharmacy and telemedicine models for medical cannabis open an opportunity

In Germany, Australia and the United Kingdom, patients increasingly get prescriptions online and receive products from pharmacies. That model resembles specialty pharmaceuticals more than retail, with standardized products and doctor oversight, so suppliers with EU good manufacturing practice certification and consistent cannabinoid profiles can win the channel. If larger EU states follow Germany, Europe's share would rise steadily, and Asia Pacific, growing at 11.17% a year, could follow through Australia.

Pennsylvania, pilot programs and hemp rules offer an opportunity

Pennsylvania, the largest medical-only U.S. state, and several states with pending adult-use bills are the biggest near-term prizes, while Switzerland and the Netherlands run regulated adult-use pilots in Europe. Closing the hemp loophole would also push delta-8 and hemp THC drink demand back into licensed stores. Each of these openings favors operators with licenses and capital ready.

Illicit supply, layered taxes and hemp loopholes cap revenue

Illicit sellers still undercut licensed prices

A large share of cannabis is still bought outside the legal channel, especially in states with high taxes or few stores. Illicit sellers avoid excise and sales taxes and undercut licensed prices, limiting how much consumption reaches regulated stores and squeezing licensed margins. States respond by licensing more stores, adjusting tax rates and enforcing against unlicensed shops, and Canada's 3,295 licensed retail businesses show how wider access helps.

Layered taxes keep many U.S. operators unprofitable

State excise, local and sales taxes raise shelf prices well above illicit prices in some states. Until broader rescheduling, adult-use operators also face federal rules blocking normal business deductions, and high effective tax rates leave many U.S. operators unprofitable, weakening investment and adding distressed license sales. Medical licensees gained relief from April 28, 2026, and the June to July 2026 hearing will decide whether adult-use sellers follow.

Federal limits raise the cost of capital

Adult-use cannabis remains in Schedule I while the DEA completes its review, so banks and payment networks stay cautious, interstate trade is banned and U.S. operators cannot list on major U.S. exchanges. These limits raise capital costs and slow expansion for multi-state operators such as Curaleaf, Trulieve and Green Thumb Industries. Operators manage with state-by-state supply chains and stronger balance sheets, but interstate commerce still requires congressional action.

Intoxicating hemp products compete at lower tax

Intoxicating hemp-derived products such as delta-8 and hemp THC drinks are sold outside cannabis licenses in many states. They compete with licensed edibles and beverages at lower tax, taking sales from the fastest-growing product category and pressuring licensed beverage makers on price. That is why licensed brands and state regulators push for federal and state limits on the hemp loophole.

U.S. and Canadian stores lead as Germany lifts Europe

North America draws most legal sales from U.S. state programs and Canada

North America held 89.2% of 2025 value and grows at 7.57% a year. The United States supplies most of the region's value through state-licensed adult-use and medical programs led by California, Michigan, Florida, Illinois and New York, with Ohio and Delaware adding sales. Canada adds steady federally legal sales across all provinces, with CAD 5.5 billion in the 2024/2025 fiscal year. Mexico, by contrast, has no regulated cannabis retail market yet.

Europe grows fastest as Germany opens its medical market

Europe held 4.1% of 2025 value and is the fastest-growing region at 16.67% a year. Germany is the largest market after its April 2024 law change, with prescriptions, imports and pharmacy sales rising fast. The United Kingdom, Poland and Italy run medical programs, while Switzerland and the Netherlands test regulated adult-use supply in pilots. EU good manufacturing practice certification is the main barrier for suppliers, which favors established Canadian, Portuguese and German producers.

Download Free Sample

Asia Pacific is a prescription-based region led by Australia

Asia Pacific held 3.6% of 2025 value and grows at 11.17% a year. Australia has the largest prescription market in the region, with online prescribing and pharmacy dispensing supporting patient growth. Thailand narrowed flower sales to prescriptions in 2025 after a period of open retail, and New Zealand runs a medical scheme. Most of Asia keeps strict bans, so growth depends on medical access in a few countries.

Middle East & Africa and Latin America rely on medical programs and export growers

The Middle East & Africa held 1.7% of 2025 value and grows at 10.17% a year. Israel has one of the world's oldest medical cannabis programs, South Africa allows private use, and several African states license cultivation mainly for export. Latin America held 1.4% and grows at 13.67% a year. Uruguay runs a legal adult-use market through pharmacies and clubs, while Colombia, Brazil and Argentina have medical programs and Colombia exports cultivated cannabis and extracts.

Download Free Sample

A Schedule III rule and two new adult-use states, 2024–2026

Low-dose formats, pharmacy quality and federal rules ahead

• Formulation advances such as better emulsions and precise low-dose gummies make beverages and edibles more consistent, supporting the fastest-growing product category at 11.77% a year.
• Extraction and vapes improve as live-resin extraction and all-in-one vape devices lift quality and convenience, helping vapes and concentrates hold value as flower prices fall.
• Medical quality standards such as EU good manufacturing practice certification and standardized cannabinoid profiles let producers sell to pharmacies in Germany, the United Kingdom and Australia.
• Telemedicine through online consultations and e-prescriptions brings medical patients to pharmacies faster, especially in Germany and Australia.
• Regulation sets the tax and capital terms for U.S. operators through Schedule III status for state-licensed medical marijuana from April 28, 2026, and the pending adult-use decision.

Multi-state operators and Canadian producers split sales

The legal cannabis market is fragmented because U.S. federal law blocks interstate trade, so no company sells in every state and thousands of single-state brands compete with a few large operators. U.S. multi-state operators, including Curaleaf, Trulieve, Green Thumb Industries, Verano Holdings and Cresco Labs, run the largest store networks; Trulieve leads in Florida's medical market, and Green Thumb and Cresco are strong in Illinois and Pennsylvania. Canadian licensed producers such as Canopy Growth, Tilray Brands, SNDL and Organigram supply provincial stores and fight price compression with brand portfolios and exports. Tilray and Aurora Cannabis also ship medical cannabis to Europe. Entry barriers are license caps in limited-license states and EU good manufacturing practice certification, while packaging rules shape costs. No company reports legal cannabis sales on a comparable basis, so no share ranking is given.

Legal cannabis operators and their roles

Tax relief and European prescriptions outweigh new votes

Credence Research's view is that legal cannabis is a large but slow-maturing retail category, and that federal tax relief and Europe's medical opening, more than new state votes, set its value through 2035. The largest new revenue lies in edibles, beverages and pre-rolls in U.S. adult-use stores and in pharmacy-dispensed medical cannabis in Germany. Operators with strong balance sheets and medical licenses are best placed, while the main risks are continued price compression and a disappointing adult-use rescheduling decision.

How Credence Research sized licensed cannabis sales

The report uses 2025 as the base year and forecasts to 2035, with CAGR calculated over 2025–2035. Market values come from Credence Research's market model, built from legal sales reported by U.S. state regulators, Canadian statistics and national medical programs, with patient numbers, licensed outlets and import permits used where no sales data exist; segment and regional splits are Credence Research estimates. Supporting evidence comes from regulator data, federal rules, statistics agencies and company filings, though unpublished data in some countries limits precision.

New formats and medical pharmacies set the pace through 2035

Through 2035, legal cannabis sales will shift further from flower toward edibles, beverages, pre-rolls and vapes, while medical demand moves toward pharmacy and telemedicine models in Europe and Australia. North America will remain the largest region, but Europe will gain share if more EU states follow Germany. Consolidation among multi-state operators will continue as weaker sellers exit. The pace will depend on whether adult-use cannabis follows medical cannabis into Schedule III, how states tax licensed products and whether hemp rules close the loophole.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.